The U.S. Food and Drug Administration recently issued an emergency use of Pfizer’s Paxlovid and Merck’s molnupiravir to treat COVID-19.
On Monday’s edition of “Closer Look” Dr. Zanthia Wiley, an Emory University infectious disease expert, discussed the science behind new antiviral drugs.
“These pills are not for prevention, they are specifically for people who are diagnosed with COVID who have early symptoms, we are talking about within five days you have symptoms and it’s for people who are at a higher risk of developing severe COVID,” Wiley said.
Read this story now for free
To continue reading, sign up for our newsletter and get unlimited access to WABE.org
You can select your preferences for news and local content. We will never share your email address. Learn how your newsletter sign-up will support WABE and Public Media
